Magenta Therapeutics

100 Technology Square, 5th Floor
Cambridge
Massachusetts
02139
United States

About Magenta Therapeutics

Magenta Therapeutics is a clinical-stage biotechnology company developing therapeutics to reset the immune system to cure more patients with devastating and life-threatening diseases. This immune reset approach can be applied through stem cell transplant to multiple diseases, including autoimmune diseases, such as multiple sclerosis and systemic sclerosis; blood cancers, such as acute myeloid leukemia; and genetic diseases, such as sickle cell disease.

Magenta's comprehensive approach to precision immune system reset will transform many aspects of the transplant process, aiming to make it safer and more effective. Our culture is fueled by a driven, passionate group of people committed making a difference, seizing opportunities to make maximum impact and pursuing progress for the patients we seek to serve.

Stock Exchange: NASDAQ

Stock Symbol: MGTA

109 articles with Magenta Therapeutics

Magenta Therapeutics Reports Third Quarter 2019 Financial Results and Recent Business Highlights

11/13/2019

Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today reported financial results for the third quarter ended September 30, 2019
Magenta Therapeutics Presents First Immune Reset Results with Antibody-Drug Conjugate Across Multiple Autoimmune Diseases at ACR

11/11/2019

Single dose of CD45-ADC shown to remove disease-causing cells and halt disease in models of multiple sclerosis, systemic sclerosis and inflammatory arthritis
Partner Magenta Therapeutics Exercises Option to Further Develop Antibody Targeted Amanitin Conjugates Targeted to CD45

11/11/2019

Heidelberg Pharma AG announced that its partner Magenta Therapeutics, Cambridge, MA, USA, declared that it will exercise the option for the exclusive worldwide development and marketing rights for Antibody Targeted Amanitin Conjugates targeting CD45.
Magenta Therapeutics to Present New Clinical and Preclinical Data at American Society of Hematology (ASH) Annual Meeting

11/6/2019

First clinical data from Phase 1 study of MGTA-145 show successful mobilization of target number of stem cells in 11 of 12 healthy volunteers within hours; updated data including apheresis collection to be presented at ASH
Magenta Therapeutics Appoints Jan Pinkas as Senior Vice President, Head of Translational Sciences and Announces Transition of Chief Scientific Officer

10/16/2019

Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today announced the appointment of Jan Pinkas, Ph.D., as Senior Vice President, Translational Sciences.
Magenta Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to MGTA-456 for the Treatment of Inherited Metabolic Disorders

9/4/2019

Magenta Therapeutics announced that the U.S. Food and Drug Administration granted Regenerative Medicine Advance Therapy designation for MGTA-456, a one-time cell therapy for the treatment of multiple inherited metabolic disorders.
Magenta Therapeutics Reports Second Quarter 2019 Financial Results and Recent Business Highlights

8/8/2019

Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today reported financial results for the second quarter ended June 30, 2019
Magenta Therapeutics to Present at the Wedbush PacGrow Healthcare Conference on Tuesday, August 13th

8/6/2019

Magenta Therapeutics announced that the Company is scheduled to present at the Wedbush PacGrow Healthcare Conference on August 13, 2019 at 3:05 p.m. ET at the Parker New York in New York City.
CORRECTING and REPLACING Magenta Therapeutics Appoints Anne McGeorge to Board of Directors

7/12/2019

Magenta Therapeutics, a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, announced that it has appointed Anne McGeorge, M.S., CPA, to its board of directors.
Magenta Therapeutics Appoints Anne McGeorge to Board of Directors

6/24/2019

Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today announced that it has appointed Anne McGeorge, M.S., CPA, to its board of directors.
Magenta Therapeutics to Present at the 40th Annual Goldman Sachs Global Healthcare Conference on Tuesday, June 11th

6/6/2019

Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today announced that the Company is scheduled to present at the Goldman Sachs Global Healthcare Conference on June 11, 2019 at 2:40 p.m. PT/5:40 p.m. ET at the Terranea Resort in Rancho Palos Verdes, Calif.
Magenta Therapeutics Presents Updated Phase 2 Clinical Data on MGTA-456 Cell Therapy at American Academy of Neurology Annual Meeting

5/9/2019

Six-month follow-up on patients with cerebral adrenoleukodystrophy (cALD) shows stable neurological function scores and early and persistent resolution of brain inflammation on MRI
Magenta Therapeutics Reports First Quarter 2019 Financial Results and Recent Business Highlights

5/9/2019

Magenta Therapeutics reported financial results for the first quarter ended March 31, 2019 and recent business highlights.
Magenta Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

5/6/2019

Magenta Therapeutics, Inc. announced the closing of its previously announced public offering of 4,887,500 shares of its common stock, including 637,500 shares of common stock sold pursuant to the underwriters’ full exercise of their option to purchase additional shares, at a price to the public of $13.25 per share.
Magenta Therapeutics Announces Pricing of Public Offering

5/2/2019

Magenta Therapeutics, Inc. announced the pricing of its public offering of 4,250,000 shares of its common stock at a price to the public of $13.25 per share, for total gross proceeds of approximately $56.3 million.
Magenta Therapeutics to Present Preclinical Data on E478 Stem Cell Gene Therapy Expansion Program at the 2019 Annual Meeting of the American Society of Gene and Cell Therapy

4/29/2019

Developing novel methods to expand gene-modified stem cells to achieve higher cell doses
Magenta Therapeutics Launches Proposed Public Offering

4/29/2019

Magenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today announced that it has launched a proposed public offering of 4,250,000 shares of its common stock.
Magenta Therapeutics Announces First Subjects Dosed in Phase 1 Clinical Trial of MGTA-145, a First-Line Stem Cell Mobilization Product Candidate

4/24/2019

Magenta intends to develop MGTA-145 in autoimmune diseases, blood cancers and genetic diseases.
Magenta Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Business Highlights

3/19/2019

Declared development candidate in first targeted conditioning program
Magenta Therapeutics to Present at Investor Conferences in March

3/6/2019

Magenta Therapeutics, a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, announced that the Company is scheduled to present at the following investor conferences: